Ribavirin

1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide

spinqualitylabelsall models Ribavirin PDB 4PB1 Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Overview Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b. Structure & Function While the main function of Ribavirin is to treat Hepatitis C and RSV, Ribavirin alone is not enough to treat these diseases and is commonly combined with interferon alfa2b. Ribavirin contains antiviral activity which inhibits DNA/RNA synthesis.The structure of Ribavirin resembles the structure of the nucleoside guanosine. Like guanosine, ribavirin is also water soluble and is able to mimic other purines as well. However, a key difference between the structure of ribavirin and the purine nucleosides is that it’s heterocyclic base contains only one ring, as opposed to purines which have two. Despite this, it is able to go through similar mechanisms as that of nucleosides such as phosphorylating into a triphosphate. It’s structural similarity to the common nucleoside guanosine may suggest how the drug can inhibit DNA/RNA synthesis through purine mimicry. Ribavirin Disease Hepatitis C Hepatitis C is an infectious disease that affects the liver due to the Hepatitis C virus (HCV). This disease can be acute or chronic and can even lead to death. By binding to the gC1qR receptor, HCV proteins are able to effectively inhibit the differentiation of helper T cells. In addition, HCV core proteins work by preventing the synthesis of the antiviral interferon IFN-γ. Thus, weakening the body’s immunity and making it susceptible to infection. Ribavirin is used in combination with peginterferon to treat Hepatitis C. By adding pegylated interferon-alpha to ribavirin, the drug had a longer half life, which required only single weekly dosing for Hepatitis C treatment. Polyethylene glycol (PEG) is covalently attached with two types:1. P-INFa-2b and 2. P-INFa-2a. While P-INFa-2b is linear and subject to hydrolysis upon injection, P-INFa-2a is branched and circulated the molecule as a whole. The limited distribution of P-INFa-2a results in a longer half life. Pneumonia Respiratory syncytial virus is responsible for viral pneumonia. This infection causes the air sacs in one or both of the lungs to become inflamed and potentially filled with fluid or pus. In infants, children, and adults over the age of 65, pneumonia can be deadly. It has been shown that Ribavirin can treat viral pneumonia by preventing transcription of respiratory syncytial virus. Mechanism Ribavirin, when administered in combination with pegylated interferon alpha, induces an antiviral state in host cells, resulting in reduced virus replication rates and activation of the host immune system. It is thought that Ribavirin acts as an antiviral agent by disrupting viral RNA synthesis, which would impact both transcription and genome replication in the Hepatitis C virus. However, the exact mechanism by which the drug interferes with this process is unknown. Several theories have been proposed to explain the effect of Ribavirin in inhibiting the replication of the Hepatitis C virus . Immunomodulation by Ribavirin may be responsible for the drug’s antiviral properties. It has been suggested that the natural CD4+ helper T cell response may be altered in the presence of Ribavirin. It is thought that ribavirin may enhance the T helper 1 response, resulting in greater clearance of virus . However, there is conflicting evidence suggesting that the T helper 2 response may be implicated in this process instead . Another possible mechanism involves the enhancement of interferon-stimulated gene (ISG) expression by Ribavirin. When a cell becomes infected with a virus, it may release interferons. Interferons are signaling molecules that function in a paracrine fashion to induce an antiviral state in neighboring cells, protecting them from infection. Ribavirin is thought to enhance the interferon signaling pathway (Feld et al), resulting in a wider antiviral response. This theory has been supported in studies using cell culture models (Thomas et al). It has also been suggested that the relationship between Ribavirin and inosine 5’-monophosphate dehydrogenase (IMPDH) may impact this process. IMPDH play a significant role in the guanine nucleotide synthesis pathway. It results in the conversion of inosine 5’-monophosphate to xanthine 5’-monophosphate, which is an intermediate for the nucleotide guanosine (Shu et al). Therefore, modulation of IMPDH activity affects a cell’s reservoir of guanosine. Ribavirin has been shown to function as a competitive inhibitor for IMPDH (Streeter et al). Because guanosine triphosphate (GTP) plays a critical role in the viral genome replication process, inhibition of IMPDH would result in the prevention of viral replication. Ribavirin has also been shown to act as an inhibitor for eIF4E, a protein of the translation initiation complex (Kentsis et al). Because of its structural similarity to guanosine, it mimics the 7-methyl guanosine mRNA cap, preventing translation. This would result in reduced capacity for viral replication within an infected cell. The Hepatitis C viral genome is replicated by RNA-dependent RNA polymerase (RdRp). A modified form of Ribavirin, Ribavirin 5’-triphosphate (RTP) is also believed to directly inhibit RdRp activity (Graci et al), resulting in lower rates of genome replication. If Ribavirin is converted to the monophosphate form, RMP, it is believed to be incorporated into the viral genome, functioning as a mutagen.

References

1. Gish, R. G. Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy. 2005, November 17;1-6. doi:10.1093/jac/dki405
2. Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 2008;47 (1), 306-320. doi: 10.1002/hep.22070
3. Paeshuyse, J, Dallmeier, K, Neyts, J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology. 2011;1(6) 590-598. doi: 10.1016/j.coviro.2011.10.030
4. National Heart, Lung and Blood Institute. Pneumonia. 2016, September 26; Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu
5. Foster, G. Pegylated interferons for the treatment of chronic Hepatitis C. Drugs. 2010;70(2):147-165. doi:10.2165/11531990-000000000-00000
6. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008, 28:1332-1343. doi: 10.1111/j.1478-3231.2008.01896.x
7. Fujimoto T, Tomimatsu M, Iga D, Endo H, Otsuka K. Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2008, 23:E432- E437. doi: 10.1111/j.1440-1746.2008.05320.x
8. Feld, JJ, Nanda, S, Huang, Y, Chen, W, Cam, M, Pusek, SN, Schwigler, LM, Theodore, D, Zacks, SL, Liang, TJ, Fried, MW. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecule pathways for treatment response. Hepatol. 2007, 46(5): 1548-1563. doi: 10.1002/hep.21853
9. Thomas E, Feld JJ, Li QS, Hu ZY, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011, 53:32-41. doi: 10.1002/hep.23985
10. Shu QN, Nair V. Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med. Res. Rev. 2008, 28:219-232. doi: 10.1002/chin.200823265
11. Streeter, DG, Witkowski, JT, Khare, GP, Sidwell, RW, Bauer, RJ, Robins, RK, Simon, LN. Mechanisms of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole) a new broad spectrum antiviral agent. Proc. Natl. Acad. Sci. 1973, 70:1174-1178. PMID: 4197928
12. Kentsis, A, Topisirovic, I, Culjkovic, B, Shao, L, Borden, KLB. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the guanosine mRNA cap. Proc. Natl. Acad. Sci. 2004, 101:18105-18110. Doi: 10.1073/pnas.0406927102
13. Graci, JD, Cameron, CE. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006, 16: 37-48. Doi: 10.1002/rmv.483

Proteopedia Page Contributors and Editors (what is this?)

Jamie Costa, Edmond R Atalla, Taylor H. Derby, Katherine Reynolds, Shannon Shaughnessy, Alexander Berchansky